CN109172670A - Chinese medicine composition and preparation method thereof with liver kidney Metabolism regulation function - Google Patents
Chinese medicine composition and preparation method thereof with liver kidney Metabolism regulation function Download PDFInfo
- Publication number
- CN109172670A CN109172670A CN201811342792.5A CN201811342792A CN109172670A CN 109172670 A CN109172670 A CN 109172670A CN 201811342792 A CN201811342792 A CN 201811342792A CN 109172670 A CN109172670 A CN 109172670A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- powder
- liver kidney
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of Chinese medicine compositions with liver kidney Metabolism regulation function, each component including following parts by weight: 3-30 parts of glossy ganoderma powder, Radix Glycyrrhizae 5-50,0.5-20 parts of witloof, 30-70 parts of Poria cocos, 50-100 parts of herba lysimachiae, 30-80 parts of dried orange peel, pueraria lobata 20-80,20-80 parts of semen plantaginis, the invention further relates to a kind of preparation methods of said medicine, including pulverize and sieve, and mix and powder processed.Chinese medicine composition raw material provided by the invention with liver kidney Metabolism regulation function are cheap and easily-available, liver kidney can be adjusted after taking, and long-time service can reduce Uric Acid level and the significant effect duration is long, additionally it is possible to improve immunity of organisms.
Description
Technical field
The invention belongs to field of Chinese medicinal composition, and in particular to a kind of Chinese medicine composition with liver kidney Metabolism regulation function
And preparation method thereof.
Background technique
The intracorporal uric acid of people is there are about 1200 milligrams, and newly-generated about 600 milligrams daily, while 600 milligrams are drained, in flat
The state of weighing apparatus.Since present many human diets are not scientific, living habit is irregular, it is easier to there is high lithemia phenomenon, and it is old
People is the main foreigner tourists of high lithemia disease since the body function of itself is weaker.Excessive uric acid is generated in vivo to have little time to drain or urinate
Sour excretion mechanism is degenerated, then internal uric acid is detained excessive, when blood uric acid concentration is greater than 7 milligrams/deciliter, human body fluid is caused to become
Acid, influences the normal function of human body cell, and gout will be caused for a long time by ignoring.Hyperuricemia patients illness initial stage belongs to no disease
Shape hyperuricemia is not in the clinical symptoms such as arthritis, high lithemia stone or kidney stone.Only blood test can just find blood
Uric acid concentration is high.But when the uric acid of hypersaturated state forms acicular crystal deposits in knuckle synovia, it can lead to acute height
Urarthritis.More seriously urate crystal is deposited on kidney and causes lesion, can cause uric acid nephropathy (i.e. pain
Wind nephrosis).
Gout is to be generated excessive due to uric acid or cause uric acid in blood to increase because uric acid excretion is bad, urate crystal deposition
The caused repeated relapsing arthritis disease in synovium of joint, synovial bursa, cartilage and its hetero-organization, this is a kind of lifelong participation disease
Disease.The patient with gout of absent renal function damage or joint deformity, normal life and work can generally be maintained by effectively being treated, less
It will affect the service life.But if malpractice, the recurrent exerbation of acute arthritis can cause larger pain.There are joint deformity and nephrolith
Then quality of life will receive certain influence to patient.Kidney function damage serious person, curative effect is poor, so once finding the state of an illness
It to treat as early as possible.The urarthritis of untreated, its severity and the speed of development also have very big difference.Some patients
All one's life only breaks out several times, however most of if do not treated, with breaking-out repeatedly, frequency and degree be in gradual exacerbation.Have
The service life that people counts patient with gout is 5 years short compared with ordinary person, but this effect completely with the situation of individual and treatment has relationship.Work as joint
Cartilage disappear, subchondral bone matter corrode and periarticular tissue infiltration, when causing gradual invalid, a small number of severe persons several years it
It is interior, that is, it can produce the serious destruction in huge tophus and joint.Influencing Most patients life is due to kidney and angiocarpy
The presence of the complication such as disease.
In the selection for inhibiting uric acid high, mainly there are two methods of western medicine and Chinese medicine treatment.Western medicine has uricosuric row
Benzbromarone, probenecid and the drug for inhibiting uric acid to generate let out have allopurinol, these poisonous side effect of medicine are big, long-term consumption
Secondary injury can be caused to body.Medically being badly in need of one kind takes safety at present, treats effective drug for adjusting internal urine
Acid, so the natural drug for selecting some toxic side effects small as far as possible carrys out anti-trioxypurine.
Although now there are many by adjusting hepatic and renal function to reduce the important composition thing of uric acid, equal raw material and
Production technology is complicated, and effect duration is short.
Summary of the invention
To solve problems of the prior art, the present invention provides a kind of Chinese medicine group with liver kidney Metabolism regulation function
Object and preparation method thereof is closed, each component including following parts by weight: 3-30 parts of glossy ganoderma powder, Radix Glycyrrhizae 5-50,0.5-20 parts of witloof,
30-70 parts of Poria cocos, 50-100 parts of herba lysimachiae, 30-80 parts of dried orange peel, pueraria lobata 20-80,20-80 parts of semen plantaginis.
Preferably, each component including following parts by weight: 10-20 parts of glossy ganoderma powder, Radix Glycyrrhizae 25-30, witloof 10-12
Part, 40-50 parts of Poria cocos, 70-75 parts of herba lysimachiae, 40-60 parts of dried orange peel, 35-55 parts of pueraria lobata, 35-55 parts of semen plantaginis.
The present invention also provides a kind of preparation methods of Chinese medicine composition with liver kidney Metabolism regulation function, according to successive
Sequence the following steps are included:
Step (1): raw material is pulverized and sieved, the raw material after weighing sieving in proportion；
Step (2): weighed sieving raw material is added to the mixer and is sufficiently mixed；
Step (3): the dosage form taken is made in the material mixed addition auxiliary material.
Preferably, the raw material includes: glossy ganoderma powder powder, licorice powder, witloof powder, Poria cocos powder, money grass meal, tangerine peel powder,
Kudzu-vine root powder, plantago powder.
In any of the above-described scheme preferably, the raw material includes ganoderma lucidum powder extracts, licorice, witloof extraction
Object, tuckahoe extracts, Herba Lysimachiae extract, dried orange peel extracts, kudzu root extract, Semen Plantaginis extract.
In any of the above-described scheme preferably, in step (1), the sieve pore of the sieve for selection of being sieved is 100 mesh.
In any of the above-described scheme preferably, in step (3), the dosage form is pulvis.
In any of the above-described scheme preferably, this law is used to prepare the above-mentioned Chinese medicine with liver kidney Metabolism regulation function
Composition and preparation method thereof.
The main component of glossy ganoderma powder is ganoderma lucidum polysaccharide, ganoderic acid, adenosine and more than 10 kinds of alkali, oleic acid, cellulose, amino
Acid, microelement etc., application range is very extensive, dirty to the heart, lung, liver,spleen,kidney etc. to have medical function, antitumor, drop blood
Sugar, liver protection, anti-aging, anti-inflammatory and antalgic, cardioprotection and anticoagulant effect.
Licorice has cortex hormone of aadrenaline effect, and anti-inflammatory, antiulcer, antianaphylaxis, anticancer, antibacterial is antiviral,
Promote pancreatic secretion, have inhibition in vitro intestines, adjusts immune function, kobadrin, anti-mutation, removing toxic substances is anti-oxidant, before protecting ear
The effects of front yard function, diuresis, liver protection prevent artery sclerosis, anti-cerebral ischemia, prevent diabetic complication.
Witloof witloof is a kind of Special plant that can be used as medicine, its mildly bitter flavor, salty, property is cold and cool, clearing heat and detoxicating and diuresis
Detumescence is its important effect, usually can be used for the treatment of the bad disease such as mankind's jaundice and damp and hot and nephritic dropsy, controls
Dosage is mostly between three to nine grams when treatment, taken with decoction based on.Clearing away heat and removing summer is also important effect of witloof, this vegetalitas
Matter is cold and cool, can eliminate the intracorporal accumulated heat of people after people are edible, has prevention well and elimination to act on the heatstroke in summer, in addition
Loss of appetite and indigestion caused by accumulating to the mankind because of heatstroke or internal heat toxin also have a good opsonic action.
Poria cocos is the dried leaf of moraceae plants mulberry.It is harvested after first frost, removes impurity, dry and obtain, be a kind of diverging wind-heat
Medicine, both oral administration, can also be applied with.Its is cold in nature, sweet in flavor, bitter, there is the effect of dispelling wind and heat from the body, clearing away the lungheat and moisturizing, clear liver and improve vision, and can treat
Anemopyretic cold, lung-heat type cough, dizziness headache, the illness of red eyes and dim-sighted
Herba lysimachiae hyoscine, have reducing fever and causing diuresis, wind-expelling pain-stopping, hemostasia and promoting granulation, eliminating inflammation and expelling toxin, desinsection function.It can control anxious slow
Property hepatitis, icteric hepatitis, cholecystitis, ephritis, urinary infection, tonsillitis, stomatitis and carbuncle malignant boil treat poison, venomous snake bite,
Acute mastitis, dysentery, malaria, empsyxis etc..
The adjustable digestive system of dried orange peel；Excited heart, enhances myocardial contractive power, and dosage is excessive to can inhibit heart rate, again
Coronary flow can be made to increase；There is certain prevention effect to artery sclerosis caused by high fat diet；It relievings asthma eliminating the phlegm；Receive Renal vascular
Contracting, makes hypourocrinia；Inhibit isolated uterine, high concentration can relax uterus；Enhance immune function；It is anti-inflammatory；Shorten bleeding and blood coagulation
Time；It can promote the digestive juice secretions such as saliva, gastric juice and eliminate enteral pneumatosis.
Pueraria lobata pueraria lobata has the effect of p- receptor blocking pharmacon, is the basis of Cardiovascular；With apparent refrigeration function；It can
Contraction or diastole smooth muscle；Also there is expansion of coronary artery and the cerebrovascular, increase coronary blood flow and cerebral blood flow (CBF),
Reduce myocardial oxygen consumption, increase oxygen supply, reduce blood pressure, it is hypoglycemic and release intestinal tube spasm the effects of.
Semen plantaginis has diuresis；Prevention kidney stone is formed；Make the tissues such as synovial membrane that arthritis occur, joint lens capsule tissue is promoted to increase
It is raw, so that the joint capsule relaxed is restored original tensity；Expelling phlegm and arresting coughing；There is quasi- choline to act on.
Chinese medicine composition raw material provided by the invention with liver kidney Metabolism regulation function are cheap and easily-available, can be with after taking
The metabolism of liver kidney is adjusted, long-time service can reduce Uric Acid level and the significant effect duration is long, additionally it is possible to
Improve immunity of organisms.
Specific embodiment
In order to be further understood that summary of the invention of the invention, the present invention is elaborated below in conjunction with specific embodiment.
Embodiment one
Raw material proportioning: 3 parts of glossy ganoderma powder, 5 parts of Radix Glycyrrhizae, 0.5 part of witloof, 30 parts of Poria cocos, 50 parts of herba lysimachiae, 30 parts of dried orange peel, Pueraria lobota
20 parts of root, 20 parts of semen plantaginis；
Preparation method: former material used is sieved, and is extracted by ganoderma lucidum powder extracts needed for raw material proportioning accurate weighing, Radix Glycyrrhizae
Object, chicory extract, tuckahoe extracts, Herba Lysimachiae extract, dried orange peel extracts, kudzu root extract, Semen Plantaginis extract.Mixing
After mixing evenly, filler is added, corrigent, rectifys the auxiliary materials such as toner and lubricant, crushes, be sieved, pulvis is made after mixing.
Embodiment two
Raw material proportioning: 10 parts of glossy ganoderma powder, 25 parts of Radix Glycyrrhizae, 10 parts of witloof, 40 parts of Poria cocos, 70 parts of herba lysimachiae, 40 parts of dried orange peel, Pueraria lobota
35 parts of root, 35 parts of semen plantaginis；
Preparation method: former material used is sieved, and is extracted by ganoderma lucidum powder extracts needed for raw material proportioning accurate weighing, Radix Glycyrrhizae
Object, chicory extract, tuckahoe extracts, Herba Lysimachiae extract, dried orange peel extracts, kudzu root extract, Semen Plantaginis extract.Mixing
After mixing evenly, filler is added, corrigent, rectifys the auxiliary materials such as toner and lubricant, crushes, be sieved, pulvis is made after mixing.
Embodiment three
Raw material proportioning: 16 parts of glossy ganoderma powder, 27 parts of Radix Glycyrrhizae, 10 parts of witloof, 45 parts of Poria cocos, 75 parts of herba lysimachiae, 55 parts of dried orange peel, Pueraria lobota
50 parts of root, 50 parts of semen plantaginis；
Preparation method: former material used is sieved, and is extracted by ganoderma lucidum powder extracts needed for raw material proportioning accurate weighing, Radix Glycyrrhizae
Object, chicory extract, tuckahoe extracts, Herba Lysimachiae extract, dried orange peel extracts, kudzu root extract, Semen Plantaginis extract.Mixing
After mixing evenly, filler is added, corrigent, rectifys the auxiliary materials such as toner and lubricant, crushes, be sieved, pulvis is made after mixing.
Example IV
Raw material proportioning: 20 parts of glossy ganoderma powder, Radix Glycyrrhizae 30,12 parts of witloof, 50 parts of Poria cocos, 75 parts of herba lysimachiae, 60 parts of dried orange peel, pueraria lobata
55 parts, 55 parts of semen plantaginis；
Preparation method: former material used is sieved, and is extracted by ganoderma lucidum powder extracts needed for raw material proportioning accurate weighing, Radix Glycyrrhizae
Object, chicory extract, tuckahoe extracts, Herba Lysimachiae extract, dried orange peel extracts, kudzu root extract, Semen Plantaginis extract.Mixing
After mixing evenly, filler is added, corrigent, rectifys the auxiliary materials such as toner and lubricant, crushes, be sieved, pulvis is made after mixing.
Embodiment five
Raw material proportioning: 30 parts of glossy ganoderma powder, Radix Glycyrrhizae 50,20 parts of witloof, 70 parts of Poria cocos, 100 parts of herba lysimachiae, 80 parts of dried orange peel, Pueraria lobota
Root 80,80 parts of semen plantaginis；
Preparation method: former material used is sieved, and is extracted by ganoderma lucidum powder extracts needed for raw material proportioning accurate weighing, Radix Glycyrrhizae
Object, chicory extract, tuckahoe extracts, Herba Lysimachiae extract, dried orange peel extracts, kudzu root extract, Semen Plantaginis extract.Mixing
After mixing evenly, filler is added, corrigent, rectifys the auxiliary materials such as toner and lubricant, crushes, be sieved, pulvis is made after mixing.
Animal experiment
The pharmaceutical composition (embodiment 1-5) for facilitating uric acid adjusting of five different dosage forms has been configured to sterile water
The solution that concentration is 10mg/mL is imitated, convenient for administration.
Material: Bioengineering Research Institute is built up in uric acid detection kit, Nanjing.
After normal male Kunming mouse overnight fasting, following eight groups are randomly divided by weight, normal group, model group, control
Treat 1 group, 2 groups for the treatment of, 3 groups for the treatment of, 4 groups for the treatment of, 5 groups for the treatment of, 6 groups, every group 8 for the treatment of.Normal group gives basal feed nursing,
Model group and treatment 1-5 group give high yeast feed (+80 basal feed of 20% yeast extract)+200mg/kg Oteracil Potassium, cause
Hyperuricemia model.Treatment 1-5 group is injected intravenously embodiment 1 respectively while modeling, embodiment 2, embodiment 3, implements
Example 4, embodiment 5, drug solution (dosage once a day 1mL/100g), normal group and model group are injected intravenously equivalent
Physiological saline.Successive administration 4 weeks.At the end of medication the 0th, 1,2,4 week, in batches after administration 3 hours, eyeball takes blood 0.5mL,
It after standing 1 hour at room temperature, is centrifuged 20 minutes under 3000rpm revolving speed, serum uric acid detection kit is taken to measure uric acid water
It is flat.Experimental result is as shown in table 1 after counting.
The variation (μm ol/L) of the serum uric acid level of 1 each group of table
Compared with model group, P < 0.05 *.
The Serum experiments data of 1 model group of analytical table are it is found that the model group serum uric acid raising when testing 1 week, at the 2nd week
Reach peak, it is still more much higher than normally organizing data although the 4th week serum uric acid level is declined, illustrate that the height is urinated
Acidaemia model has continuous stability, designs very successful.It treats serum uric acid value of the 1-5 group at the 1st week and has reached peak,
But the numerical value (P < 0.05) of respectively less than model group.At the 2nd week, the uric acid level for the treatment of 1-5 group declines to a great extent, and controls within the 4th week
The uric acid level for treating 1-5 group is no different with normal group.It to sum up analyzes, illustrates that the embodiment herbal composite for treating 1-5 group all has
Inhibit uric acid to be formed, promotes uric acid excretion, reduce the effect of serum uric acid.
Clinical test
Effect of the invention is further described in detail below with reference to the clinical test that hospital carries out.
150 hyperuricemia patients are divided into six groups, take embodiment 1, embodiment 2, embodiment 3, embodiment 4, reality respectively
The Chinese medicine composition of example 5 is applied, in the morning, afternoon and evening each 1 time daily, is continuously taken 30 days.Detect the uric acid water before and after patient on medication
It is flat, the curative effect of herbal composite of the present invention is judged with this, table 2 is therapeutic effect of each embodiment to human body hyperuricemia.
Therapeutic effect of each embodiment of table 2 to hyperuricemia
From the data of table 2 it is found that six embodiment drugs are significant to the therapeutic effect of hyperuricemia, treated effect
Greater than 97%.During clinical test and the concrete condition of patient is tracked.
Curative effect monitoring
So that this 150 hyperuricemia patients pauses is used Chinese medicine composition provided by the invention, measured patient's every 15 days
Uric acid level monitors the lasting effect of herbal composite of the present invention with this.Table 3 is curative effect monitoring situation.
Lasting effect of 3 present invention of table to hyperuricemia
As known from Table 3, Chinese medicine composition provided by the invention uric acid level just meeting after 45 days that patient cuts out
Rise, illustrates that the significant in efficacy and duration of Chinese medicine composition is long.
It will be apparent to those skilled in the art that the Chinese medicine composition and its system with liver kidney Metabolism regulation function of the invention
Preparation Method includes the summary of the invention and specific embodiment part of aforementioned present invention specification, as space is limited and to make to illustrate letters
Bright each scheme without constituting these combinations describes one by one.All within the spirits and principles of the present invention, that is done is any
Modification, equivalent replacement, improvement etc., should all be included in the protection scope of the present invention.
Claims (8)
1. a kind of Chinese medicine composition with liver kidney Metabolism regulation function, each component including following parts by weight: glossy ganoderma powder 3-
30 parts, Radix Glycyrrhizae 5-50,0.5-20 parts of witloof, 30-70 parts of Poria cocos, 50-100 parts of herba lysimachiae, 30-80 parts of dried orange peel, pueraria lobata 20-80,
20-80 parts of semen plantaginis.
2. the Chinese medicine composition according to claim 1 with liver kidney Metabolism regulation function, which is characterized in that including following
The each component of parts by weight: 10-20 parts of glossy ganoderma powder, Radix Glycyrrhizae 25-30,10-12 parts of witloof, 40-50 parts of Poria cocos, herba lysimachiae 70-75
Part, 40-60 parts of dried orange peel, 35-55 parts of pueraria lobata, 35-55 parts of semen plantaginis.
3. a kind of preparation method of the Chinese medicine composition with liver kidney Metabolism regulation function, includes following step according to sequencing
It is rapid:
Step (1): raw material is pulverized and sieved, the raw material after weighing sieving in proportion；
Step (2): weighed sieving raw material is added to the mixer and is sufficiently mixed；
Step (3): the dosage form taken is made in the material mixed addition auxiliary material.
4. the preparation method of the Chinese medicine composition according to claim 3 with liver kidney Metabolism regulation function, feature exist
In the raw material includes: glossy ganoderma powder powder, licorice powder, witloof powder, Poria cocos powder, money grass meal, tangerine peel powder, kudzu-vine root powder, semen plantaginis
Powder.
5. the preparation method of the Chinese medicine composition according to claim 3 with liver kidney Metabolism regulation function, feature exist
It include ganoderma lucidum powder extracts in, the raw material, licorice, chicory extract, tuckahoe extracts, Herba Lysimachiae extract is old
Bark extract, kudzu root extract, Semen Plantaginis extract.
6. the preparation method of the Chinese medicine composition according to claim 3 with liver kidney Metabolism regulation function, feature exist
In in step (1), the sieve pore of the sieve for selection of being sieved is 100 mesh.
7. the preparation method of the Chinese medicine composition according to claim 3 with liver kidney Metabolism regulation function, feature exist
In in step (3), the dosage form is pulvis.
8. the preparation method of the Chinese medicine composition according to claim 3 with liver kidney Metabolism regulation function, feature exist
In the Chinese medicine composition being used to prepare described in any one of claims 1 or 2 with liver kidney Metabolism regulation function and its preparation
Method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811342792.5A CN109172670A (en) | 2018-11-13 | 2018-11-13 | Chinese medicine composition and preparation method thereof with liver kidney Metabolism regulation function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811342792.5A CN109172670A (en) | 2018-11-13 | 2018-11-13 | Chinese medicine composition and preparation method thereof with liver kidney Metabolism regulation function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109172670A true CN109172670A (en) | 2019-01-11 |
Family
ID=64939273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811342792.5A Pending CN109172670A (en) | 2018-11-13 | 2018-11-13 | Chinese medicine composition and preparation method thereof with liver kidney Metabolism regulation function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109172670A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110302329A (en) * | 2019-08-16 | 2019-10-08 | 海南贵本南药科技有限公司 | A kind of composition with anti-trioxypurine and preparation method thereof, application |
| CN112057553A (en) * | 2020-09-30 | 2020-12-11 | 广西玉林巨安保健品有限公司 | Uric acid reducing composition and preparation method and application thereof |
| CN115154538A (en) * | 2022-08-02 | 2022-10-11 | 无限极（中国）有限公司 | Traditional Chinese medicine composition with blood uric acid reducing effect and application thereof |
| CN115501281A (en) * | 2022-09-06 | 2022-12-23 | 赵杰 | Traditional Chinese medicine composition for reducing uric acid and preparation method thereof |
| CN115554345A (en) * | 2022-05-09 | 2023-01-03 | 福建中医药大学附属第二人民医院（福建省第二人民医院） | A Chinese medicinal compound preparation for treating gout and hyperuricemia, and its preparation method |
| CN115607596A (en) * | 2022-12-06 | 2023-01-17 | 山西振东五和医养堂股份有限公司 | Health wine with uric acid reducing effect and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103100006A (en) * | 2013-01-30 | 2013-05-15 | 无限极（中国）有限公司 | Chinese herbal medicine composition with uric acid reducing function |
| CN103340936A (en) * | 2013-07-11 | 2013-10-09 | 唐淑萍 | Traditional Chinese medicine for treating primary gout |
| CN105481758A (en) * | 2016-01-13 | 2016-04-13 | 天津药物研究院有限公司 | Lomitapide crystal form I as well as preparation method and application thereof |
-
2018
- 2018-11-13 CN CN201811342792.5A patent/CN109172670A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103100006A (en) * | 2013-01-30 | 2013-05-15 | 无限极（中国）有限公司 | Chinese herbal medicine composition with uric acid reducing function |
| CN103340936A (en) * | 2013-07-11 | 2013-10-09 | 唐淑萍 | Traditional Chinese medicine for treating primary gout |
| CN105481758A (en) * | 2016-01-13 | 2016-04-13 | 天津药物研究院有限公司 | Lomitapide crystal form I as well as preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 尹德铭等: "金钱草加味汤治疗原发性高尿酸血症 30 例", 《江西中医药》 * |
| 徐蕾: "《痛风中医特色疗法》", 30 June 2012, 人民军医出版社 * |
| 王绪前等: "《中药材彩色图谱》", 31 May 2015, 中国医药科技出版社 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110302329A (en) * | 2019-08-16 | 2019-10-08 | 海南贵本南药科技有限公司 | A kind of composition with anti-trioxypurine and preparation method thereof, application |
| CN112057553A (en) * | 2020-09-30 | 2020-12-11 | 广西玉林巨安保健品有限公司 | Uric acid reducing composition and preparation method and application thereof |
| CN115554345A (en) * | 2022-05-09 | 2023-01-03 | 福建中医药大学附属第二人民医院（福建省第二人民医院） | A Chinese medicinal compound preparation for treating gout and hyperuricemia, and its preparation method |
| CN115554345B (en) * | 2022-05-09 | 2024-01-26 | 福建中医药大学附属第二人民医院（福建省第二人民医院） | A Chinese medicinal compound preparation for treating gout and hyperuricemia, and its preparation method |
| CN115154538A (en) * | 2022-08-02 | 2022-10-11 | 无限极（中国）有限公司 | Traditional Chinese medicine composition with blood uric acid reducing effect and application thereof |
| CN115154538B (en) * | 2022-08-02 | 2023-05-05 | 无限极（中国）有限公司 | Traditional Chinese medicine composition with blood uric acid reducing effect and application thereof |
| CN115501281A (en) * | 2022-09-06 | 2022-12-23 | 赵杰 | Traditional Chinese medicine composition for reducing uric acid and preparation method thereof |
| CN115607596A (en) * | 2022-12-06 | 2023-01-17 | 山西振东五和医养堂股份有限公司 | Health wine with uric acid reducing effect and preparation method thereof |
| CN115607596B (en) * | 2022-12-06 | 2023-12-19 | 山西振东五和医养堂股份有限公司 | Health wine with uric acid reducing effect and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109172670A (en) | Chinese medicine composition and preparation method thereof with liver kidney Metabolism regulation function | |
| CN109674958B (en) | Traditional Chinese medicine composition with effect of reducing uric acid and preparation method and application thereof | |
| CN115252692A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating diseases related to hyperuricemia | |
| CN109172770A (en) | Facilitate the herbal composite and preparation method thereof of uric acid adjusting | |
| CN107412713A (en) | Treat Chinese patent drug, dietetic food and the preparation method of autoimmune and immune related diseases | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN109125631A (en) | Chinese medicine composition and preparation method thereof with liver kidney regulatory function | |
| CN112057501A (en) | Traditional Chinese medicine composition, traditional Chinese medicine ointment and external hot compress plaster for treating muscular atrophy and myasthenia | |
| CN1313120C (en) | Application of ciliate bugle herb piece in preparing medicine for treating scapulohumeral periarthritis | |
| CN1060053C (en) | Proprietary traditional Chinese medicine for anti-senility and the prepn. method | |
| CN108310169A (en) | Pharmaceutical composition and preparation method thereof for preventing osteoarthritis | |
| CN103341108B (en) | Pharmaceutical composite for treating stress urinary incontinence after prostatectomy | |
| CN104524359B (en) | A kind of Chinese medicine composition, its preparation method and application | |
| CN103301372B (en) | Preparation method of umbilicus dressing agent for treating post-operation prostate stress urinary incontinence | |
| CN112826888B (en) | Traditional Chinese medicine composition for gout and preparation method and application thereof | |
| CN115252700B (en) | Traditional Chinese medicine composition and medicine for treating cervical tinnitus and preparation method thereof | |
| CN108653554B (en) | A Chinese medicinal composition for treating respiratory system diseases, and its preparation method | |
| CN111298061B (en) | Traditional Chinese medicine composition for clearing heat and detoxicating, removing stasis and resolving masses and preparation method thereof | |
| CN109419844B (en) | Tibetan medicine composition for treating osteoarthritis pain | |
| CN107213443B (en) | Traditional Chinese medicine composition for treating hydronephrosis and combined application of thunder-fire moxibustion | |
| CN105194676A (en) | Medicine composition for treating hyperlipemia and preparation method of medicine composition | |
| CN105327024A (en) | Traditional Chinese medicine preparation for treating rheumatoid arthritis | |
| CN104606426A (en) | Traditional Chinese medicinal composition preparation for treating chronic gastritis and preparation method thereof | |
| CN104606377A (en) | Traditional Chinese medicinal composition for treating gastritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190111 |